Advanced Liver Cancer
10
3
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (10)
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer
Plasmodium Immunotherapy for Breast and Liver Cancers
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer
Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer